Market size, share and growth analysis by therapy, cancer type, route of administration and pet type, across all major regions and key countries, with forecasts for 2024–2033. The competitive landscape profiles 15 companies.
The global pet cancer therapeutics market was valued at USD 527 Mn in 2024 and is projected to reach USD 1.16 Bn by 2033, growing at a CAGR of 9.2%. Europe is the largest regional market and Asia-Pacific is growing fastest.
Reports Description
As per the current market research conducted by the CMI Team, the global Pet Cancer Therapeutics Market is expected to record a CAGR of 9.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 526.5 Million. By 2033, the valuation is anticipated to reach USD 1,162.4 Million.
Global Pet Cancer Therapeutics Market 2024–2033 (By Million)
The Pet Cancer Therapeutics market refers to the segment of the veterinary industry dedicated to developing and providing treatments for cancer in companion animals. It encompasses a wide range of pharmaceuticals, biologics, and therapeutic interventions designed to diagnose, manage, and treat various types of cancer in pets.
With the growing prevalence of cancer in companion animals and the increasing demand for advanced veterinary care, the Pet Cancer Therapeutics market plays a crucial role in addressing the healthcare needs of pets affected by cancer, improving their quality of life, and supporting their owners through treatment options and support services.
Pet Cancer Therapeutics Market - Significant Growth Factors
Increasing Pet Ownership: The rising number of pet owners, coupled with the growing trend of pet humanization, has led to increased spending on pet healthcare, including cancer therapeutics.
Advancements in Veterinary Medicine: Ongoing advancements in veterinary oncology, including new treatment modalities, diagnostic tools, and targeted therapies, are driving the development of innovative cancer therapeutics for pets.
Rising Incidence of Pet Cancer: The increasing prevalence of cancer among companion animals, attributed to factors such as environmental pollutants, genetic predispositions, and aging populations, is boosting the demand for effective cancer therapeutics.
Growing Awareness and Education: Pet owners are becoming more aware of the signs and symptoms of cancer in pets, leading to earlier diagnosis and intervention. This heightened awareness, coupled with increased education efforts by veterinary professionals, is driving demand for pet cancer therapeutics.
Personalized Medicine for Pets: The emergence of personalized medicine approaches, such as genomic testing and targeted therapies, presents an opportunity to tailor cancer treatments to the individual needs of pets, improving treatment outcomes and minimizing side effects.
Expansion of Telemedicine and Remote Consultations: The adoption of telemedicine and remote consultations in veterinary oncology allows for greater access to specialized care, particularly in underserved areas. This presents an opportunity to expand the reach of pet cancer therapeutics and improve patient outcomes through remote diagnosis, treatment planning, and follow-up care.
Pet Cancer Therapeutics Market - Mergers and Acquisitions
The Pet Cancer Therapeutics Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Pet Cancer Therapeutics Market include:
In 2023, Hill's Pet Nutrition introduced Prescription Diet ONC Care, a therapeutic pet diet aimed at addressing appetite loss and providing high-quality nutrition for cats and dogs diagnosed with cancer. This specialized diet is designed to support the unique nutritional needs of pets undergoing cancer treatment.
In 2022, Boehringer Ingelheim and CarthroniX have partnered to advance canine oncology by developing innovative small molecule therapeutics. This collaboration aims to address the unmet medical needs of dogs diagnosed with cancer, leveraging CarthroniX's expertise in small molecule-based therapies.
In 2021, PetDx, a San Diego-based startup, raised USD 62 million in its Series B funding round to expand the adoption of its cancer-detecting blood test for dogs, known as OncoK9. The company aims to make OncoK9 a standard test in pet clinics nationwide.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Pet Cancer Therapeutics Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
Pet Cancer Therapeutics Market - Significant Threats
The Pet Cancer Therapeutics Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
High Treatment Costs: The cost of cancer treatment for pets can be prohibitively expensive for some pet owners, leading to financial constraints and potential delays or refusal of treatment, which could impact the demand for pet cancer therapeutics.
Limited Access to Specialized Care: Limited access to specialized veterinary oncology services in certain regions may restrict pet owners' ability to seek advanced cancer treatments for their pets, affecting the adoption and utilization of pet cancer therapeutics.
Regulatory Challenges: Stringent regulatory requirements for veterinary drugs and therapies, including clinical trial regulations and approval processes, can pose challenges for companies developing and commercializing pet cancer therapeutics, potentially delaying market entry and innovation.
Competition from Alternative Therapies: Competition from alternative therapies, such as holistic treatments, herbal remedies, or dietary supplements, may divert pet owners' attention and resources away from traditional pet cancer therapeutics, impacting market demand and revenue potential.
Limited Awareness and Education: Lack of awareness and education among pet owners about the availability and benefits of pet cancer therapeutics, as well as misconceptions about treatment options and outcomes, may hinder market growth and adoption of advanced cancer treatments for pets.
Category-Wise Insights:
By Therapy
Chemotherapy: Chemotherapy involves the use of drugs to kill cancer cells or slow their growth. In the Pet Cancer Therapeutics Market, chemotherapy remains a primary treatment modality, with ongoing trends focusing on the development of more targeted and less toxic chemotherapy agents tailored to pets' needs.
Immunotherapy: Immunotherapy boosts the body's immune system to fight cancer. In the Pet Cancer Therapeutics Market, immunotherapy is gaining traction as a promising treatment option, with trends emphasizing the development of novel immunotherapeutic agents and personalized immunotherapy approaches for pets.
Targeted Therapy: Targeted therapy blocks specific molecules involved in cancer cell growth. In the Pet Cancer Therapeutics Market, targeted therapy is experiencing rapid growth, with trends focusing on the discovery of new molecular targets, precision medicine approaches, and the development of targeted therapeutics tailored to pets' genetic profiles.
Combination Therapy: Combination therapy involves using multiple treatment modalities simultaneously or sequentially to enhance efficacy. In the Pet Cancer Therapeutics Market, combination therapy is a growing trend, with research focusing on identifying synergistic treatment combinations and optimizing treatment regimens to improve outcomes for pets with cancer.
By Cancer Type
Lymphoma: Lymphoma is a common cancer affecting lymphocytes. In the pet cancer therapeutics market, advancements in targeted therapies and immunotherapies have improved treatment outcomes. Rising incidence rates and increasing demand for personalized medicine are driving market growth.
Mast Cell Cancer: Mast cell cancer involves abnormal growth of mast cells. In the pet cancer therapeutics market, targeted therapies and surgical interventions are key treatment modalities. Growing awareness and early detection initiatives are influencing market trends.
Melanoma: Melanoma is a malignant tumor arising from melanocytes. In the pet cancer therapeutics market, innovative immunotherapies and vaccine-based treatments show promise. Increasing prevalence and advancements in early diagnosis are shaping market dynamics.
Mammary and Squamous Cell Cancer: Mammary and squamous cell cancer affect glandular and epithelial tissues, respectively. In the pet cancer therapeutics market, surgical excision and chemotherapy are common treatment approaches. Rising incidence rates and efforts to improve treatment efficacy are key trends.
Others: Other types of pet cancers include osteosarcoma, hemangiosarcoma, and oral tumors. The pet cancer therapeutics market addresses these cancers through a combination of surgery, chemotherapy, and radiation therapy. Continued research and development efforts drive innovation in treatment options for these cancers.
By Route of Administration
Oral: Oral administration involves delivering pet cancer therapeutics through the mouth, typically in the form of tablets, capsules, or liquids, allowing for convenient and non-invasive treatment options. The oral route of administration is witnessing growth due to the development of novel oral formulations and increased preference for at-home treatments, enhancing convenience for pet owners.
Injection: Injection administration delivers pet cancer therapeutics directly into the body through subcutaneous, intramuscular, or intravenous routes, providing rapid and targeted delivery of medications. Injections are gaining popularity in the Pet Cancer Therapeutics Market due to advancements in injectable formulations, such as long-acting formulations and targeted drug delivery systems, improving treatment efficacy and patient compliance.
By Pet Type
Dog: In the pet cancer therapeutics market, canine cancer therapeutics refer to treatments tailored specifically for dogs diagnosed with cancer. Trends include increasing adoption of targeted therapies and immunotherapies, advancements in surgical techniques, and a growing focus on personalized medicine approaches to improve treatment outcomes for canine cancer patients.
Cat: Feline cancer therapeutics in the pet cancer therapeutics market are specialized treatments designed for cats diagnosed with cancer. Trends include the development of novel chemotherapy agents and radiation therapies specifically formulated for feline patients, as well as advancements in diagnostic imaging technologies for early detection and treatment monitoring in cats with cancer.
Report Scope
Feature of the Report
Details
Market Size in 2024
USD 526.5 Million
Projected Market Size in 2033
USD 1,162.4 Million
Market Size in 2023
USD 482.1 Million
CAGR Growth Rate
9.2% CAGR
Base Year
2023
Forecast Period
2024-2033
Key Segment
By Therapy, Cancer Type, Route of Administration, Pet Type and Region
Report Coverage
Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options
Request tailored purchasing options to fulfil your requirements for research.
Pet Cancer Therapeutics Market - Regional Analysis
North America: In North America, the pet cancer therapeutics market is characterized by a high level of technological advancements and a strong focus on research and development. Trends include the increasing adoption of personalized medicine approaches, such as genomic testing and targeted therapies, as well as the growing demand for minimally invasive surgical techniques and novel immunotherapies for pets diagnosed with cancer.
Europe: In Europe, the pet cancer therapeutics market is influenced by a growing emphasis on preventive care and early detection of cancer in pets. Trends include the expansion of pet insurance coverage for cancer treatments, the adoption of telemedicine and remote consultations in veterinary oncology, and the implementation of comprehensive cancer screening programs for companion animals.
Asia-Pacific: The Asia-Pacific region is experiencing rapid growth in the pet cancer therapeutics market due to increasing pet ownership rates and rising disposable incomes. Trends include the emergence of specialized veterinary oncology centers and cancer treatment facilities, the adoption of alternative and complementary therapies for pets with cancer, and the development of affordable and accessible cancer treatments tailored to the unique needs of pets in the region.
LAMEA (Latin America, Middle East, and Africa): In LAMEA, the pet cancer therapeutics market is characterized by a growing awareness of pet health issues and a rising demand for advanced veterinary care. Trends include the expansion of veterinary oncology services in urban centers, the adoption of telemedicine and digital health solutions to improve access to cancer diagnostics and treatment, and the development of culturally relevant and affordable cancer therapeutics for pets in emerging markets.
Competitive Landscape – Pet Cancer Therapeutics Market
The Pet Cancer Therapeutics Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:
Zoetis Inc.
Elanco Animal Health
Boehringer Ingelheim Animal Health
Virbac
Aratana Therapeutics
AB Science
VetDC Inc.
Regeneus Ltd.
CanFel Therapeutics
Merial
Karyopharm Therapeutics Inc.
Rhizen Pharmaceuticals SA
Vetoquinol S.A.
Ceva Santé Animale
Sentia Medical Sciences Inc.
Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
New players entering the pet cancer therapeutics market are adopting innovative approaches to differentiate themselves and gain traction. Companies like PetVivo Holdings Inc., OncoPet Diagnostics, and VetDC, Inc. are leveraging advancements in biotechnology, diagnostics, and targeted therapies to develop novel cancer treatments for pets.
Meanwhile, key players such as Zoetis Inc., Elanco Animal Health, and Boehringer Ingelheim Animal Health dominate the market due to their extensive product portfolios, global presence, established distribution networks, and strong research and development capabilities, which enable them to offer comprehensive solutions and maintain market leadership.
Which are the driving factors of the Pet Cancer Therapeutics Market?
The key factors driving the Market are Increasing Pet Ownership, Advancements in Veterinary Medicine, Rising Incidence of Pet Cancer, Growing Awareness and Education, Personalized Medicine for Pets And Expansion of Telemedicine and Remote Consultations.
Which type led the Pet Cancer Therapeutics market?
The "Lymphoma" category dominated the market in 2023.
Who are the key players in the Pet Cancer Therapeutics market?
The key players in the market are Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim Animal Health, Virbac, Aratana Therapeutics, AB Science, VetDC Inc., Regeneus Ltd., CanFel Therapeutics, Merial, Karyopharm Therapeutics Inc., Rhizen Pharmaceuticals SA, Vetoquinol S.A., Ceva Santé Animale, Sentia Medical Sciences Inc., Others.
Which region held the largest market share in the Pet Cancer Therapeutics market?
"North America" had the largest share in the Pet Cancer Therapeutics Market.
What is the growth rate of the Pet Cancer Therapeutics market?
The global market is projected to grow at a CAGR of 9.2% during the forecast period, 2024-2033.
How much is the Pet Cancer Therapeutics market?
The Pet Cancer Therapeutics Market size was valued at USD 526.5 Million in 2024.
Ayush Kadam is a Senior Market Research Analyst at Custom Market Insights, with over seven years of experience in syndicated and custom market research. He specializes in market sizing, competitive intelligence, industry trends, forecasting, and strategic insights, helping clients turn complex data into actionable business decisions.
